Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.33 |
| ▸ | CES1 | P23141 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10646394 | 0.78 | CES2 (0.30) | CES2CES1 | |
| SCHEMBL8039763 | 0.78 | CES2 (0.30) | CES2CES1 | |
| SCHEMBL8119940 | 0.78 | HDAC1 (0.32) | — | |
| SCHEMBL8116818 | 0.78 | CES2 (0.30) | CES2CES1 | |
| SCHEMBL7700727 | 0.77 | TRPV4 (0.33) | CES2CES1 | |
| SCHEMBL2513757 | 0.76 | TRPV4 (0.30) | — | |
| SCHEMBL9209444 | 0.75 | HDAC1 (0.31) | — | |
| SCHEMBL10651560 | 0.75 | — | — | |
| SCHEMBL7557368 | 0.75 | TRPV4 (0.39) | — | |
| SCHEMBL18245388 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506176-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2013-04-24 | — | — | EP | claimed |
| US-8034936-B2 | Spirocyclic cyclohexane compounds useful to treat substance dependency | GRUENENTHAL GMBH (DE) | 2011-10-11 | — | — | US | claimed |
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | GRUENENTHAL GMBH (DE) | 2011-03-03 | — | — | US | claimed |
| EP-0236673-B1 | Process for quinoline-3-carboxylic acid antibacterial agents | WARNER LAMBERT CO (US) | 1994-07-13 | — | — | EP | claimed |
| EP-0239992-B1 | PROCESS FOR THE PREPARATION OF 2,3,4,5-TETRAFLUOROBENZOYL ACETATES | WARNER-LAMBERT COMPANY (US) | 1989-09-06 | — | — | EP | claimed |
| EP-0126355-B1 | 7-AMINO-1-CYCLOPROPYL-6,8-DIFLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLINE-CARBOXYLIC ACID, PROCESSES FOR THEIR PREPARATION AND ANTIBACTERIAL AGENTS CONTAINING THEM | BAYER AG (DE) | 1987-09-09 | — | — | EP | claimed |
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | UNIV KYOTO (JP) | 2023-09-07 | — | — | US | disclosed |
| EP-4164891-A1 | FLUORESCENT COMPOSITION COMPRISING AT LEAST ONE BENZAZOLE COMPOUND FOR THE SECUREMENT OF PRODUCTS | Crime Science Technology (FR) | 2023-04-19 | — | — | EP | disclosed |
| WO-2021250358-A1 | FLUORESCENT COMPOSITION COMPRISING AT LEAST ONE BENZAZOLE COMPOUND FOR THE SECUREMENT OF PRODUCTS | Crime Science Technology (FR) | 2021-12-16 | — | — | WO | disclosed |
| CN-108774219-B | Small molecule compound for inhibiting PD-1/PD-L1 and application thereof | 中国药科大学 | 2021-05-04 | — | — | CN | disclosed |
| CN-109232316-B | Synthetic method of alpha-tertiary nitrile structure beta-dicarbonyl compound | 昆明学院 | 2021-03-26 | — | — | CN | disclosed |
| CN-106674254-B | Quinolone carboxylic acid compounds and intermediates, preparation method and application thereof | 广东省中医院 | 2019-03-15 | — | — | CN | disclosed |
| CN-109251211-A | A kind of quinolonecarboxylic acid compound and its intermediate, preparation method and application | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2019-01-22 | — | — | CN | disclosed |
| WO-2000004914-A1 | NOVEL FLUORESCENCE DYES AND THEIR APPLICATIONS FOR WHOLE CELL FLUORESCENCE SCREENING ASSAYS FOR CASPASES, PEPTIDASES, PROTEASES AND OTHER ENZYMES AND THE USE THEREOF | CYTOVIA, INC. (US) | 2000-02-03 | — | — | WO | disclosed |
| EP-0718277-B1 | Method for producing 5-substituted-2-acylaminophenols, and 5-alkyl-2-acylaminophenol compound and N-acyl-N-(4-alkyl-phenyl)hydroxylamine compound | FUJI PHOTO FILM CO LTD (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0718277-A1 | Method for producing 5-substituted-2-acylaminophenols, and 5-alkyl-2-acylaminophenol compound and N-acyl-N-(4-alkyl-phenyl)hydroxylamine compound | FUJI PHOTO FILM CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
| EP-0680482-A1 | PROCESS FOR THE MANUFACTURE OF A TRICYCLIC COMPOUND. | PFIZER (US) | 1995-11-08 | — | — | EP | disclosed |
| US-4977263-A | USING CHEMICAL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-12-11 | — | — | US | disclosed |
| EP-0274033-A1 | Process for the preparation of quinolinecarboxylic acids | BAYER AG (DE) | 1988-07-13 | — | — | EP | disclosed |
| EP-0239992-A1 | Process for the preparation of 2,3,4,5-tetrafluorobenzoyl acetates | WARNER-LAMBERT COMPANY (US) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053970-A1 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency | TACR2, OPRK1, OPRD1 | CES2 9/4885CES1 196/4885CA1 2404/4885 |
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | VDR, CYP24A1, CYP2R1 | CES2 3086/4885CES1 180/4885CA1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.